Novocure's board approved a major compensation increase for Chief Science Officer Dr. Uri Weinberg.
The raise is linked to Weinberg's new dual role as CSO and President of Innovative Treatments.
The move aims to retain leadership and align pay with strategic growth goals in oncology.
It reflects the critical importance of advancing the TTFields therapy pipeline into new cancer types.
๐ Full Retelling
Novocure, the oncology-focused medical device company, has announced significant increases in executive compensation for its Chief Science Officer, Dr. Uri Weinberg, effective immediately. The decision was formalized by the company's board of directors at its headquarters in St. Helier, Jersey, following a review of executive roles and responsibilities. This move is directly tied to Dr. Weinberg's recent appointment to the dual roles of Chief Science Officer and President of Novocure's Innovative Treatments business, a strategic expansion of his duties aimed at accelerating the development and commercialization of the company's Tumor Treating Fields (TTFields) therapy platform.
The compensation adjustments reflect the heightened strategic importance of Dr. Weinberg's combined leadership position. As President of Innovative Treatments, he now oversees the critical pipeline of new applications for TTFields technology beyond its current use in glioblastoma and mesothelioma. This includes pivotal clinical trials in non-small cell lung cancer, pancreatic cancer, and other solid tumors. The board's decision to substantially increase his base salary, annual bonus potential, and long-term equity awards is framed as a necessary step to retain top-tier talent and align executive incentives with the company's ambitious long-term growth objectives, particularly as it navigates key regulatory and commercial milestones.
This executive compensation revision occurs against a backdrop of intense scrutiny on corporate governance and pay practices within the healthcare technology sector. For Novocure, which is heavily invested in proving the efficacy of its novel cancer treatment across multiple indications, securing and motivating key scientific leadership is paramount. The enhanced compensation package is intended not only to reward Dr. Weinberg's past contributions but also to incentivize the successful execution of a complex clinical and commercial strategy that is central to the company's future valuation and its mission to provide new options for cancer patients worldwide.
Uri Weinberg (Hebrew: ืืืจื ืืื ืืจื; 24 March 1937 โ 6 March 2012) was an Israeli footballer. He played in two matches for the Israel national football team from 1961 to 1962.
Alternating electric field therapy, sometimes called tumor treating fields (TTFields), is a type of electromagnetic field therapy using low-intensity, intermediate frequency electrical fields to treat cancer. TTFields disrupt cell division by disrupting dipole alignment and inducing dielectrophoresi...
